Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study.

Li Chen,Shao Zhi-min,Zhonghua Wang,Wentao Yang,Yi Zhou Jiang,Jianjun Zou,Jiong Wu,Genhong Di,Guangyu Liu,Ke Da Yu,Lei Fan,Junjie Li,Yifeng Hou,Zhen Hu,Canming Chen,Xiaoyan Huang,A-Yong Cao,Xin Hu,Songyang Wu,Shen Zhao

Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study.

2021

Li Chen
Shao Zhi-min
Zhonghua Wang
Wentao Yang
Yi Zhou Jiang
Jianjun Zou
Jiong Wu
Genhong Di
Guangyu Liu
Ke Da Yu
Lei Fan
Junjie Li
Yifeng Hou
Zhen Hu
Canming Chen
Xiaoyan Huang
A-Yong Cao
Xin Hu
Songyang Wu
Shen Zhao

1007Background: Camrelizumab (anti-PD-1 antibody) and nab-paclitaxel (nab-P) have demonstrated promising anti-tumour activity in patients with immunomodulatory (IM) subtype metastatic triple negati...

Keywords:

Internal medicine
Medicine
in patient
Oncology
Phases of clinical research
Nab-paclitaxel
Antibody
first line treatment
Triple-negative breast cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations